GROWING GOLD RESOURCES IN QUEBEC'S ABITIBI TSX: WM OTCQB: WLBMF wallbridgemining.com TSX: WM | OTCQB: WLBMF Cautionary Note Regarding Forward-Looking Information This presentation contains forward-looking statements or information (collectively, "FLI") within the meaning of applicable Canadian securities legislation. FLI is based on expectations, estimates, projections, and interpretations as at the date of this presentation. All statements, other than statements of historical fact, included herein are FLI ...

Summary of Oric Pharmaceuticals FY Conference Call Company Overview - **Company**: Oric Pharmaceuticals (NasdaqGS:ORIC) - **Industry**: Clinical stage oncology - **Focus Areas**: Prostate cancer, lung cancer, and breast cancer [2][3] Key Programs 1. **Rinzimetostat (ORIC-944)**: - Allosteric PRC2 inhibitor targeting prostate cancer in combination with AR inhibitors (apalutamide and darolutamide) [2][3] - Phase III study expected to start in the first half of 2026 [3][4] - Early clinical data shows promising PSA response rates and favorable safety profile compared to Pfizer's data [5][17] 2. **Enosertinib**: - EGFR inhibitor with high potency on exon 20 and PAK mutations [3][43] - Demonstrated 100% overall response rate in patients with measurable disease, including those with untreated brain metastases [43] Market Opportunity - **Prostate Cancer**: - Large patient population with significant unmet needs; over $11 billion in sales for ARPi inhibitors last year [23][24] - Potential to reverse resistance to current therapies and extend treatment duration [24][25] - **Lung Cancer**: - High prevalence of CNS metastases in lung cancer patients, making CNS activity a critical differentiator for enosertinib [43][44] Competitive Landscape - **Rinzimetostat vs. Mevrometostat**: - Rinzimetostat is positioned as a potentially best-in-class PRC2 inhibitor with better drug properties, including solubility and half-life [11][12] - Early data suggests lower rates of gastrointestinal and hematological toxicities compared to competitors [17] - **Enosertinib's Differentiation**: - Focus on CNS activity and less off-target toxicities compared to competitors [43][44] Upcoming Milestones - **Rinzimetostat**: - Q1 update with data from 20-25 patients expected, focusing on PSA50, PSA90, safety, and tolerability [38][39] - Phase III study initiation in the first half of 2026 [3][38] - **Enosertinib**: - Continued evaluation of monotherapy and combination strategies, with updates expected in the second half of 2026 [48][49] Investor Considerations - The stock's performance is closely tied to the outcomes of the MEVPRO-1 study and the company's own data releases [53][56] - Rinzimetostat is viewed as a potential blockbuster if it demonstrates differentiation in safety and efficacy [58] Conclusion Oric Pharmaceuticals is strategically positioned in the oncology space with promising drug candidates targeting significant unmet needs in prostate and lung cancers. The upcoming data releases and competitive positioning will be critical for investor confidence and stock performance moving forward.

Logitech International (NasdaqGS:LOGI) FY Conference February 25, 2026 12:00 PM ET Speaker1 Hi, good morning, everyone. Can everyone hear us okay? Great. I'm Mark Newman, Bernstein's US IT hardware analyst. Great to see you all here this morning, and great pleasure to welcome today, Henk Faber, CEO of Logitech. Thanks for joining us today. Speaker0 Thanks for having us. Speaker1 Great. I've got a few prepared questions I'm gonna go through. Happy to open up to the audience. You should have some app. You sho ...

Financial Data and Key Metrics Changes - Total revenues for the first quarter reached $632 million, a decrease of 6% year-over-year, primarily due to a 12% reduction in home deliveries [6][7] - Adjusted gross margin was 13.4%, slightly below expectations, while SG&A expenses were 13.3%, better than the low end of guidance [5][6] - Adjusted EBITDA was $63 million, significantly higher than guidance, and adjusted pre-tax income was $31 million, also above forecast [6][7] Business Line Data and Key Metrics Changes - Income from unconsolidated joint ventures totaled $3 million, slightly below expectations, while income from consolidated joint ventures exceeded expectations with a gain of $27 million recorded as other income [6][21] - The percentage of Quick Move-in homes (QMIs) in total sales decreased from 79% to 71%, while to-be-built sales increased from 21% to 29% [16][19] Market Data and Key Metrics Changes - Monthly traffic per community increased significantly, with January showing a 40% year-over-year increase, indicating improved buyer engagement [11] - Contracts in February 2026 were up 13% compared to the prior year, suggesting a positive trend in sales activity [12] Company Strategy and Development Direction - The company is focused on maintaining a steady sales pace and efficiently turning over existing inventory while preparing for new land opportunities that promise improved margins [10][20] - The strategy includes prioritizing the acquisition of land for move-up homes in prime locations and expanding active adult communities, moving away from lower-margin developments [20][27] Management's Comments on Operating Environment and Future Outlook - Management acknowledged ongoing challenges in the housing market but expressed confidence in meeting homebuyer demand and improving profitability in the latter half of 2026 [36][39] - The company expects adjusted pre-tax income to improve in the second half of 2026, supported by stronger contract activity and the delivery of higher-margin homes [37][39] Other Important Information - The company ended the quarter with $471 million in liquidity, which is above target, and has significantly reduced net debt while increasing equity [28][30] - The net debt-to-capital ratio improved to 41.4%, a substantial decrease from 146.2% at the start of fiscal 2020 [30] Q&A Session Summary Question: On the topic of incentives and their pressure on margins, is there an opportunity to offer less incentives for higher margins? - Management prefers to focus on sales pace rather than price, maintaining incentives to clear lower-margin land and drive liquidity [43] Question: What is the current percentage of Quick Move-in homes versus built-to-order homes? - The percentage of QMIs has dropped to 71%, while built-to-order sales have increased, reflecting market demand rather than a strategic shift [44]

Financial Data and Key Metrics Changes - Total revenues for the first quarter reached $632 million, a 6% decrease compared to the previous year, primarily due to a 12% reduction in home deliveries [5][6][7] - Adjusted gross margin was 13.4%, slightly below expectations, while SG&A expenses were 13.3%, better than the low end of guidance [5][6] - Adjusted EBITDA was $63 million, significantly higher than guidance, and adjusted pre-tax income was $31 million, also above forecasted ranges [6][7] - Income from unconsolidated joint ventures totaled $3 million, slightly below expectations, while income from consolidated joint ventures exceeded expectations with a gain of $27 million recorded as other income [6][21] Business Line Data and Key Metrics Changes - The company delivered 12% fewer homes year-over-year, impacting total revenues, but a land sale helped offset some of the decline [6][7] - Incentives accounted for 12.6% of the average sales price, with a significant increase in mortgage rate buydowns contributing to affordability challenges [8][15] - The percentage of Quick Move-in homes (QMIs) in total sales decreased from 79% to 71%, while to-be-built sales increased from 21% to 29% [16][17] Market Data and Key Metrics Changes - Monthly traffic per community increased significantly in five of the six months shown, with January showing a 40% increase year-over-year [11] - Contracts in February 2026 were up 13% compared to the prior year, indicating a positive trend in buyer engagement [12] - The company experienced fluctuations in contracts over the past 12 months, with January showing an 11% year-over-year gain [11][12] Company Strategy and Development Direction - The company is focused on efficiently turning over existing inventory and advancing sales of Quick Move-in homes while preparing for new land opportunities that promise improved margins [10][20] - A shift in land acquisition strategy is underway, moving away from lower-margin entry-level homes to more move-up homes in prime locations and active adult communities [20][27] - The company aims to maintain a disciplined approach to land management, walking away from less attractive opportunities and focusing on higher-margin developments [24][26] Management's Comments on Operating Environment and Future Outlook - Management acknowledged ongoing challenges in the housing market, including affordability pressures and economic uncertainties, but expressed confidence in meeting homebuyer demand [36][39] - The expectation for adjusted pre-tax income is to improve in the latter half of 2026, supported by stronger contract activity and the delivery of higher-margin homes [37][39] - The company remains committed to sustainable growth and value for shareholders, with a focus on inventory efficiency and land-light operations [39][40] Other Important Information - The company ended the quarter with $471 million in liquidity, above target, and has seen a significant reduction in net debt [28][30] - The net debt-to-capital ratio improved to 41.4%, a substantial decrease from 146.2% at the start of fiscal 2020 [30] - The company is only providing financial guidance for the next quarter due to current market volatility and challenges in predicting margins [31] Q&A Session Summary Question: On the topic of incentives and their pressure on margins, is there an opportunity to offer less incentives for higher margins? - Management prefers to focus on sales pace rather than price, maintaining incentives to clear lower-margin land and drive liquidity [43] Question: What is the current percentage of Quick Move-in homes versus built-to-order homes? - The percentage of QMIs has dropped to 71%, while demand for built-to-order homes has been increasing, which is beneficial due to higher profit margins [44]

Financial Data and Key Metrics Changes - Total revenues for Q1 2026 reached $632 million, a 6% decrease compared to the previous year, primarily due to a 12% reduction in home deliveries [8][10] - Adjusted gross margin was 13.4%, slightly below expectations, while SG&A expenses were 13.3%, better than the low end of guidance [5][6] - Adjusted EBITDA for the quarter was $63 million, significantly higher than guidance, and adjusted pre-tax income was $31 million, also above forecast [6][10] Business Line Data and Key Metrics Changes - Income from unconsolidated joint ventures totaled $3 million, slightly below expectations, while income from consolidated joint ventures exceeded expectations with a gain of $27 million recorded as other income [6][22][23] - The company delivered 12% fewer homes year-over-year, impacting overall revenues, but a land sale helped offset some of the decline [8][10] - Incentives accounted for 12.6% of the average sales price, with a significant increase in mortgage rate buydowns contributing to affordability challenges [9][15] Market Data and Key Metrics Changes - Monthly traffic per community increased significantly in 5 of the 6 months leading up to January 2026, with January showing a 40% increase compared to the same month last year [12] - Contracts per community held steady at about 9.5 for the past 3 years, with February 2026 contracts on track to be higher than the same month last year [13][14] - The company experienced fluctuations in contracts over the past 12 months, with January showing an 11% year-over-year gain [12] Company Strategy and Development Direction - The company is focused on efficiently turning over existing inventory and advancing sales of Quick Move-in homes while preparing for new land opportunities that promise improved margins [11][21] - A shift in land acquisition strategy is noted, moving away from lower-margin entry-level homes to more move-up homes in prime locations and active adult communities [21][29] - The company aims to maintain a disciplined approach to land management, walking away from less attractive opportunities and focusing on higher-margin developments [28][29] Management's Comments on Operating Environment and Future Outlook - Management acknowledged ongoing challenges in the housing market, including affordability pressures and economic uncertainties, but expressed confidence in meeting homebuyer demand [38][41] - The expectation for adjusted pre-tax income is to improve in the latter half of 2026, supported by stronger contract activity and the delivery of higher-margin homes [40][42] - The company remains committed to sustainable growth and value for shareholders, with a focus on inventory efficiency and land-light operations [42][43] Other Important Information - The company ended Q1 2026 with $471 million in liquidity, above target, despite significant spending on land and stock repurchases [29][30] - The net debt-to-capital ratio improved to 41.4%, a significant reduction from previous years, indicating stronger financial health [32] - The company expects to provide financial guidance for the next quarter only, reflecting the current market volatility [33] Q&A Session Summary Question: On the topic of incentives and their pressure on margins, is there an opportunity to offer less incentives for higher margins? - Management prefers to focus on sales pace rather than price, maintaining incentives to clear lower-margin land and drive liquidity [45][46] Question: What is the current percentage of Quick Move-in homes versus built-to-order homes? - Quick Move-in sales dropped from 79% to 71%, not due to a strategic shift but rather market demand, with built-to-order homes showing higher profit margins [48][49]

Financial Data and Key Metrics Changes - Adjusted net investment income for Q4 2025 was $0.32 per share, covering the $0.32 per share dividend paid on December 31, 2025 [4] - Net asset value (NAV) declined to $11.52 per share from $12.06 per share, primarily due to lower valuation on Edmentum [5][25] - Total investment income for the quarter was $77 million, a 4% decrease compared to the prior quarter [35] - Total net expenses decreased by 5% to $44 million, including a fee waiver [35] Business Line Data and Key Metrics Changes - Approximately 95% of the loan portfolio is ranked green, with no positions rated red [8][24] - The company sold $477 million of assets, diversifying the portfolio and reducing PIK income [12][18] - Senior-oriented assets now represent 81% of the portfolio, up from 75% in the prior year [19][32] Market Data and Key Metrics Changes - The company expects to see some spread widening and increased pricing dispersion in direct lending [28] - Approximately 41% of pro forma PIK income will be generated by high-performing companies like Benevis and UniTek [20] Company Strategy and Development Direction - The company plans to utilize the full Dividend Protection Program, reducing the incentive fee from 20% to 15% until the end of 2026 [12] - Following the asset sale, the company aims to redeploy proceeds primarily into first lien assets [19][32] - The company is focused on business building and leveraging its expertise in software loans, particularly in the context of AI [10][22] Management's Comments on Operating Environment and Future Outlook - Management believes NMFC shares should trade back towards book value, citing several positive factors [11] - The company acknowledges increased risks related to AI but sees opportunities for well-informed lenders [22] - Management remains optimistic about the potential for equity appreciation in companies like UniTek [16] Other Important Information - The company repurchased approximately $52 million of shares in 2025 and has authorization to buy an additional $80 million [16] - Nonaccruals remain low at 1.4% of the portfolio at fair value [26] Q&A Session Summary Question: Is the 94% discount on the asset sale inclusive of any advisory fees? - The 94% of par was the purchase price, with expected fees and expenses of about $7 million [41] Question: Did the company try to sell any struggling assets? - The company focused on reducing concentration and PIK income, selling larger positions that were scrutinized by the market [44][45] Question: How were the assets selected for the sale? - The assets were chosen based on concentration and PIK characteristics, aiming to improve portfolio composition [51][52] Question: How does the pricing of the assets compare to internal marks? - The sale was seen as fair for both sides, validating internal marks while reducing concentration [61]

Keros Therapeutics Conference Call Summary Company Overview - **Company**: Keros Therapeutics (NasdaqGM: KROS) - **Industry**: Biopharmaceuticals - **Focus**: Discovery, development, and commercialization of treatments for disorders linked to dysfunctional signaling of the TGF-beta superfamily of proteins, targeting pathways critical for blood cell growth, repair, and maintenance across various tissues [1][3] Core Products and Development - **Lead Candidate**: KER-065 (Rinvatercept) - **Indications**: Developed for neuromuscular diseases, specifically Duchenne muscular dystrophy (DMD) and amyotrophic lateral sclerosis (ALS) [2][4] - **Mechanism**: A modified activin receptor ligand trap designed to inhibit TGF-beta ligands, promoting muscle regeneration, increasing muscle size and strength, and reducing fibrosis and inflammation [5][11] - **Partnered Drug**: Elritercept - **Indications**: Developed for treating ineffective hematopoiesis in myelodysplastic syndromes (MDS) and myelofibrosis (MF) [2][21] - **Partnership**: Global license agreement with Takeda, including an upfront payment of $200 million and potential milestones exceeding $1.1 billion [21] Clinical Insights - **Duchenne Muscular Dystrophy (DMD)** - **Prevalence**: Approximately 1 in 3,500 male births [8] - **Current Treatments**: Glucocorticoids (short-term benefits), exon skippers (limited benefit), gene therapy (declining efficacy) [10] - **Potential of KER-065**: Increases muscle mass, decreases fat mass, improves bone mineral density, and reduces negative effects of glucocorticoids [11][14] - **Amyotrophic Lateral Sclerosis (ALS)** - **Patient Population**: Approximately 30,000 patients in the U.S. [16] - **Mechanism of Action**: Aims to preserve muscle function and quality of life by promoting muscle regeneration and potentially counteracting muscle atrophy [19] Financial Overview - **Current Financial Position**: As of the third quarter, Keros reported $383 million in cash, providing a runway into the first half of 2028 [24][25] - **Investment in Trials**: Funds allocated for phase 2 trials and advancing preclinical assets into clinical development [25] Upcoming Milestones - **DMD Trial**: Expected to start in the current quarter [24] - **ALS Trial**: Engagement with regulators planned for the second half of the year [24] - **Elritercept Phase 3 RENEW Trial**: Ongoing, with Takeda committed to starting frontline treatment in the 2025 fiscal year [26] Additional Insights - **Research and Development**: Keros has a proprietary library of modified activin receptor II ligand traps and is exploring a broad range of indications, including neurodegenerative diseases and obesity [22][23] - **Clinical Data**: Phase 1 study of KER-065 showed it was well tolerated with no serious adverse events, indicating a favorable safety profile compared to earlier molecules [13][14] This summary encapsulates the key points from the Keros Therapeutics conference call, highlighting the company's focus, product pipeline, clinical insights, financial status, and future milestones.

MBX Biosciences FY Conference Summary Company Overview - **Company**: MBX Biosciences (NasdaqGS:MBX) - **Focus**: Pioneering Precision Endocrine Peptides (PEPs) for treating endocrine and metabolic disorders [1][4] Key Updates and Expectations for 2026 - **Pivotal Year**: 2026 is expected to be crucial with significant milestones across three clinical stage programs and advancements in obesity discovery and preclinical development [1] - **Cash Runway**: The company has a cash runway extending into 2029, providing flexibility in advancing its pipeline [3] Clinical Programs Canvuparatide - **Phase II Meeting**: An end-of-phase II meeting with the FDA is scheduled, with updates on study design for phase III expected [2] - **Phase II Update**: One-year data will be released in Q2, with a global registrational phase III study initiation planned for Q3 [2] - **Response Rate**: A 63% response rate was observed in a 12-week placebo-controlled study, with 79% of patients responding during the open-label extension [9][10] Obesity Portfolio - **MBX-4291**: A once-monthly GLP-1/GIP co-agonist with anticipated 12-week data from a multiple ascending dose study [2] - **New Candidates**: Two additional candidate selections targeting amylin and glucagon are expected in Q2 and Q3 [2] Imapextide - **Phase IIa Study**: A pharmacodynamic study is underway for post-bariatric hypoglycemia, with results expected in Q2 2024 [24][25] Technology and Differentiation - **PEP Technology**: The proprietary PEP technology allows for slow release and steady exposure, improving tolerability and reducing side effects associated with traditional therapies [4][19] - **Best-in-Class Potential**: The company aims to develop best-in-class drugs, with positive feedback from the physician community regarding their clinical data [12][15] Market Opportunity - **Hypoparathyroidism**: The disease has a prevalence of over 250,000 in the US and EU, with current treatments being inadequate [7] - **Obesity Treatment**: The company recognizes obesity as a heterogeneous disease requiring diverse therapeutic options, with a focus on improving tolerability and adherence [18] Financial Position - **Cash Balance**: Year-end cash balance of $373 million, projected to increase to $460 million post recent stock sale, supporting operations through 2029 [34][35] - **Commercialization Plans**: Preparations for the commercialization of canagliflozin are underway, with a focus on recruiting a Chief Commercial Officer [36] Conclusion - **Growth Potential**: MBX Biosciences is positioned for a catalyst-rich year with multiple data releases and a strong pipeline aimed at addressing significant health issues in endocrine and metabolic disorders [33][36]

Financial Data and Key Metrics Changes - Q4 revenue grew by 13.7% and Q4 EBITDA increased by 37.6% [4] - Gross margin for the quarter finished at 41.9%, relatively flat compared to Q3 [10] - Net income attributable to stockholders increased by 50.7% to $13.4 million, reflecting an 11% net income margin [22] - EPS for the quarter was $0.48, and for the year, net income attributable to stockholders grew 12.6% to $51.2 million, with a 10.8% net income margin [22] Business Line Data and Key Metrics Changes - Total window film product line grew by 10% in Q4 and 21.7% for the year, driven by market share gains in auto and Windshield Protection Film [19] - Total installation revenue increased by over 17% in the quarter and 17.2% for the year [19] - Corporate store, dealership, service business, and aftermarket all saw growth in their respective segments [5] Market Data and Key Metrics Changes - U.S. region revenue grew by 11% in Q4, despite ongoing market dynamics [4] - Canada experienced a slight revenue decline, with car sales down 13% sequentially in Q4 [9] - Europe showed strong performance with revenue growing by 26.8% in Q4 [9] - China revenue came in at $14 million, higher than expected, marking the first full quarter post-acquisition [8] Company Strategy and Development Direction - The company is focused on investments in manufacturing and supply chain to support growth in key markets [4][16] - A strategic pivot has been made to concentrate on core products and improve sales efficiency [13][14] - The company aims to enhance its DAP platform and integrate it further into customer operations [12] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism for 2026, citing increased customer engagement and positive feedback from the dealer conference [17][50] - The company anticipates a rebound in EV sales through its referral channel and expects gross margins to improve as the year progresses [10][11] - Management acknowledged headwinds in Canada and the impact of weather on Q1 performance but remains confident in overall growth prospects [9][31] Other Important Information - The effective tax rate for the quarter was just under 14%, with a future planning assumption of a 21% effective rate [21] - Cash flow from operations was $2.7 million for the quarter and $66.9 million for the year, representing a 40% increase from the previous year [24] Q&A Session Summary Question: What is contemplated in the Q1 revenue guide? - Management acknowledged the impact of weaker auto demand and weather on Q1 performance but indicated that they have factored these elements into their guidance [27][30] Question: How do you see in-house manufacturing playing out over time? - Management indicated that the build-out could be gradual or involve larger chunks depending on decisions made in the coming months [33][35] Question: Can you provide more color on the increase in DSO? - Management noted that the increase in DSO is likely due to new OEM business with longer payment terms, but there is nothing alarming [39][43] Question: What underpins your optimism for 2026? - Management highlighted increased optimism from customers, structural improvements in vehicle affordability, and a positive pipeline of new customer wins as key factors [50][53] Question: How do you expect gross margin to trend this year? - Management expects gross margin headwinds to abate in Q1, with improvements anticipated in Q2 as pricing issues resolve [55][57]